Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 0.55 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.53 |
| ▸ | TUBB | P07437 | 4/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30306119 | 1.00 | TOP2A (0.55) | TOP2ATOP2BKDM4EKMT2ACNR1 | |
| SCHEMBL2339241 | 1.00 | TOP2A (0.55) | TOP2ATOP2BKDM4EKMT2ACNR1 | |
| SCHEMBL20125115 | 0.92 | TOP2A (0.55) | TOP2ATOP2BKDM4EKMT2ACNR1 | |
| SCHEMBL19751491 | 0.92 | TOP2A (0.55) | TOP2ATOP2BKDM4EKMT2ACNR1 | |
| SCHEMBL15828544 | 0.90 | TOP2A (0.54) | TOP2ATOP2BKDM4EKMT2ACNR1 | |
| SCHEMBL11200216 | 0.90 | TOP2A (0.49) | TOP2ATOP2BKDM4EKMT2ACNR1 | |
| SCHEMBL10835611 | 0.90 | TOP2A (0.54) | TOP2ATOP2BKDM4EKMT2ACNR1 | |
| SCHEMBL25374200 | 0.90 | CNR2 (0.67) | TOP2ATOP2BKDM4EKMT2ACNR1 | |
| SCHEMBL30542704 | 0.90 | CNR2 (0.67) | TOP2ATOP2BKDM4EKMT2ACNR1 | |
| SCHEMBL1344388 | 0.89 | CNR1 (0.58) | TOP2ATOP2BKDM4EKMT2ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-60075489-A | — | — | None | — | — | JP | disclosed |
| WO-2023158862-A2 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20070244318-A1 | Process for the Preparation of Levofloxacin Hemihydrate | RAO DAVULURI R | 2007-10-18 | — | — | US | disclosed |
| US-6229017-B1 | BY ACYLATION AND CYCLIZATION OF A BENZOYL CHLORIDE OR NICOTINOYL CHLORIDE IN THE PRESENCE OF A NON-POLAR TO SLIGHTLY POLAR SOLVENT WITHOUT SEPARATION OF CHEMICAL INTERMEDIATES DURING PROCESS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-05-08 | — | — | US | disclosed |
| EP-0206283-B1 | OPTICALLY ACTIVE PYRIDOBENZOXAZINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-01-27 | — | — | EP | disclosed |
| US-5153203-A | QUINOLONE DERIVATIVES AND SALTS THEREOF, PREPARATION PROCESSES THEREOF, AND ANTIBACTERIAL AGENTS CONTAINING THE SAME | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1992-10-06 | — | — | US | disclosed |
| US-5142046-A | Optically active pyridobenzoxazine derivatives and intermediates thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1992-08-25 | — | — | US | disclosed |
| US-5053407-A | OPTICALLY ACTIVE PYRIDOBENZOXAZINE DERIVATIVES AND ANTI-MICROBIAL USE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| US-4985557-A | OFLOXACIN INTERMEDIATE | DAIICHI SEIYAKU CO., LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| EP-0390215-A2 | Quinolone derivatives and salts thereof, preparation process es thereof, and antibacterial agents containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1990-10-03 | — | — | EP | disclosed |
| US-4958045-A | ENAMINES, BACTERICIDES, ANIMAL GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1990-09-18 | — | — | US | disclosed |
| US-4859773-A | Preparation of 1,8-bridged 4-quinoline-3-carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1989-08-22 | — | — | US | disclosed |
| US-4826985-A | Intermediates for preparation of racemate and optically active ofloxacin and related derivatives | ABBOTT LABORATORIES (US) | 1989-05-02 | — | — | US | disclosed |
| US-4777253-A | Process for preparation of racemate and optically active ofloxacin and related derivatives | ABBOTT LABORATORIES (US) | 1988-10-11 | — | — | US | disclosed |
| US-4762831-A | PROMOTE ANIMAL GROWTH | BAYER AKTIENGESELLSCHAFT (DE) | 1988-08-09 | — | — | US | disclosed |
| JP-S6075489-A | BORON CHELATE COMPOUND | DAI ICHI SEIYAKU CO LTD | 1985-04-27 | — | — | JP | disclosed |
| EP-0047005-B1 | BENZOXAZINE DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1984-11-14 | — | — | EP | disclosed |
| US-4382892-A | Benzoxazine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1983-05-10 | — | — | US | disclosed |
| EP-0047005-A1 | Benzoxazine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1982-03-10 | — | — | EP | disclosed |
| JP-S0675489-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244318-A1 | Process for the Preparation of Levofloxacin Hemihydrate | RTF1, CYP2F1, CYP4F11 | TOP2A 744/4885TOP2B 1081/4885KDM4E 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.